Paul Bleicher, MD PhD is the Chief Executive Officer of Optum Labs, an open, collaborative health care innovation center established by Mayo Clinic and Optum to attract research partnerships between various stakeholder groups in healthcare and accelerate the “speed of innovation” in the pursuit of improved patient health.
Prior to his current role, he was Chief Medical Officer for Humedica, a next-generation clinical informatics company that provides novel business intelligence solutions to the health care and life science industry. He built and managed Humedica’s analytic operations, was responsible for clinical strategy and oversight and led the company’s product management and regulatory affairs teams. His leadership was instrumental to many Humedica innovations; including products that help care providers improve the quality and timeliness of care, to new ways of understanding and predicting disease, to sophisticated approaches to analyzing clinical data. Humedica was acquired by Optum in 2013.
Before Humedica, Dr. Bleicher was a founder of, and spent 11 years building and guiding the growth of Phase Forward, which led the transformation of pharmaceutical clinical trials from paper to the web. He was the original Chief Executive Officer of Phase Forward where he served in various capacities and as a member of the Board of Directors until its 2010 acquisition by Oracle Corporation. Dr. Bleicher had previously served as Vice President of Clinical Affairs at Alpha-Beta Technology with responsibility for Phase I through III clinical development of a novel anti-infective carbohydrate drug. Dr. Bleicher began his career in industry as a leader of the Early Phase Services consulting group at PAREXEL International where he assisted pharmaceutical and biotechnology companies with the initial development of novel therapies.
Dr. Bleicher is a member of the Institute of Medicines Roundtable on Value and Science-Driven Healthcare and currently serves on the editorial boards of Applied Clinical Trials and the Drug Information Journal. He has held various leadership positions in the Drug Information Association, including Chairman of the Steering Committee of North America for the Drug Information Association, a member of their Board of Directors and a member of the Board of the DIA Foundation. He also served as a member of the Massachusetts Life Sciences Leadership Council.
In 2002, Dr. Bleicher won the Ernst and Young Entrepreneur of the Year Award in New England and was appointed to the Ernst and Young Entrepreneur’s Hall of Fame. He was in the first group of PharmaVoice’s 100 Most Inspiring Leaders in Life Sciences, and was named a Champion in Healthcare by the Boston Business Journal. He was named the 2003 recipient of the Rensselaer Alumni Association Fellows Award, and the 2011 Alumni Key Award.
Dr. Bleicher received his BS from Rensselaer Polytechnic Institute, and his MD and PhD from the University of Rochester School of Medicine and Dentistry, specializing in cellular immunology. He trained in internal medicine at the Beth Israel Hospital, and dermatology at Harvard Medical School/Massachusetts General Hospital. He did a post-doctoral fellowship at the Dana Farber Cancer Institute in molecular biology, and began his career as a physician/investigator and Assistant Professor at the Massachusetts General Hospital and Harvard Medical School.